GF
CASC

Gerstein Fisher’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Gerstein Fisher’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,833
Closed -$24K – 429
2015
Q4 		$24K Buy
1,833
+166
+10% +$2.86K ﹤0.01% 403
2015
Q3 		$27K Buy
+1,667
New +$34.2K ﹤0.01% 399
2015
Q2 		– Sell
-2,667
Closed -$26K – 436
2015
Q1 		$26K Hold
2,667
– – ﹤0.01% 405
2014
Q4 		$30K Hold
2,667
– – ﹤0.01% 384
2014
Q3 		$31K Hold
2,667
– – 0.01% 380
2014
Q2 		$52K Hold
2,667
– – 0.01% 333
2014
Q1 		$48K Sell
2,667
-2,833
-52% -$46.5K 0.01% 328
2013
Q4 		$58K Buy
5,500
+3,000
+120% +$33.5K ﹤0.01% 444
2013
Q3 		$31K Buy
+2,500
New +$26.3K 0.01% 359

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gerstein Fisher's CASC Position: Q1 2016 in Review

Gerstein Fisher sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2016, closing a stake of 1,833 shares — an estimated $24K sold.

Gerstein Fisher first reported a position in CASC in Q3 2013 and held it in 9 quarters. The position peaked at $58K in Q4 2013. 80 funds tracked by Wall St. Rank hold CASC as of Q1 2016.

  • Gerstein Fisher reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Gerstein Fisher sold 1,833 Cascadian Therapeutics, Inc. shares in Q1 2016, an estimated $24K.
  • Gerstein Fisher first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 9 quarters.
  • Gerstein Fisher's Cascadian Therapeutics, Inc. position peaked at $58K in Q4 2013.
  • 80 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2016.

Based on Gerstein Fisher's 13F filing for Q1 2016, filed 12 May 2016.